IPhO is pleased to announce the addition of another new student chapter to our growing national network and recognize UMSOP student leaders Caryn Gordon, Nam Nguyen, and Leena Doolabh for their commitment to bringing IPhO to UMSOP!
Congratulations to student pharmacists at University of Maryland-Baltimore School of Pharmacy. IPhO now connects them to a national network of 4,000 student pharmacists with similar interests, as well as a national network of 440 industry fellows and 10,000 industry pharmacists.
Several more schools are in the late stages of filing their chapter applications and will soon join the growing national network.
To start a chapter at your school, visit here.
For the student benefits of joining IPhO, view the National Student Brochure here!
Thursday, August 17, 2017 - The Pharma Collaboration for Transparent Medical Information, known as phactMI™, is pleased to announce the publication of the MI Code of Practice. Written by phactMI members, the Code of Practice provides pharmaceutical-company MI professionals with standards to guide their responses to healthcare professional requests.
“The MI Code of Practice articulates standards that Industry MI professionals follow in responding to questions about their respective products,” says Dominick Albano, Vice President, Global Medical Information, Pfizer and Board of Directors, phactMI. “It reflects the integrity with which we approach our work, which supports the safe, effective, and appropriate use of medicines, thereby ultimately benefiting patients.”
MI professionals have access to scientifically accurate, up to date information on their products. As such, they are able to support healthcare professionals in their commitment to provide quality patient care. The Code of Practice provides guidance to MI professionals centered on three core elements:
- Clinical and pharmaceutical expertise
- Scientific balance of medical responses
- Quality standards
“I think it is important that Healthcare professionals who utilize industry MI services or who are considering using MI services know who we are and what we stand for,” continues Albano. “I think the same is true for patients and caregivers. The Code of Practice helps provide this understanding and can serve to increase trust.”
The phactMI Code of Practice can be accessed at:
MAPS, the Medical Affairs Professional Society, is a non-profit global society of Medical Affairs professionals across a spectrum of fields, experience and locales. I chose to be a part of MAPS because it is the only society BY Medical Affairs professionals, FOR Medical Affairs professionals. Medical Affairs as a designated function has only been around for about 25-30 years which is relatively young compared to other functional areas in the industry. I believe in the vision of MAPS to elevate the role of medical affairs to be an equal partner to other functions, and lead the industry in the education of customers for the greater benefit of patients.
Pharmacists such as myself in the pharmaceutical industry can benefit from MAPS by expanding their understanding of medical affairs from true industry leaders, and networking through engaging professional events. I encourage you to explore the opportunities and resources that MAPS can provide you!
Visit HERE to learn more about MAPS!
Ramin Farhood, PharmD, MBA, Vice President and Head, Global Medical Affairs, AveXis, and MAPS Executive Leadership Committee Member
Authored by Alyssa Bowling, PharmD, Medical Information/Medical Affairs Fellow 2016-18, MCPHS University. The views and opinions represented below are those of the author alone, and should not be attributed to any organization with which the author is employed or affiliated.
A decade ago, the idea of “patient-centricity” in pharmaceutical industry was brand new; however, it has quickly become commonplace in nearly every company. It seems that conversations take place daily to evaluate how companies can shift focus from viewing patients as merely customers to instead seeing them as the group that drives and directs company initiatives. Rather than communicating solely with healthcare professionals to discuss products, the industry is moving toward engaging patients to better understand their personal experiences and to uncover unmet needs.
As the 2016-17 Fellowship year officially comes to an end, several IPhO National Fellows Council (NFC) members have successfully completed their industry fellowships/residencies and accepted their first full time industry positions. We recognize and congratulate them, and all the outgoing fellows, on this significant accomplishment!
Outgoing NFC Leaders
- Alex Wei, PharmD
- Matthew Schmidt, PharmD
- Joyce Cao, PharmD
- Vatche Demirjian, PharmD
- Nicholas Heath, PharmD
- Gediminas Pliura, PharmD
- Alisha Couto, PharmD
- Phil Armendi, PharmD
The 2016-17 term has been an extremely exciting and productive period for our National Student Officers. We want to take this moment to acknowledge each of them and some of their numerous accomplishments. IPhO increased its national student leadership from three to six members this past year to support the continuing growth of our organization. During their tenure, the number of IPhO Student Chapters grew to 48! This growth would not have been possible without the tremendous commitment and quality of these student pharmacist leaders.
In addition, we are pleased to congratulate each of them on their acceptance to an industry fellowship program.
2016-17 IPhO National Student Officers
Bridgette Tran, PharmD
NSO, Chapter Management
Fellow, Daiichi- Sankyo Medical Affairs
On April 19, 2017 the MCPHS-Boston IPhO Chapter hosted its 4th Annual “Emerging World of the Industry Pharmacist” event on the MCPHS-Boston campus. The focus of this year's event was, "The Rise of Rare Diseases and its Growing Impact on Healthcare."
100+ Industry experts, pharmacists, fellows, and students gathered to gain more insight on the growing impact of rare diseases in the pharmaceutical industry. The evening began with a networking session followed by dinner and presentations from three industry experts who work with rare diseases on a daily basis.
Dr. James Alexander, CEO and Founder of IPhO, moderated the event and spoke of the importance of rare diseases in the pharmaceutical industry and the unique role it has within all departments.
Jonathan Picker, MD, PhD from Boston Children's hospital shared his personal experience of launching Fragile X and Global Gene Corp, two multinational biotech companies that deliver genomics data platform solutions for various patients, including those with rare diseases. Will Richmond, MBA, Senior Director of Market Access Sanofi Genzyme, spoke about his individual experience of engaging with various specialists and finding patients from the rare disease population. Concluding the presentation was Georgina Lee, PharmD, Associate Director of Regulatory Affairs with Biogen. Dr. Lee discussed the fast track approval for rare disease drugs, granted by the FDA and how these medications receive a faster response in regards to the submission of their advertising and promotional material.
Bernie Tyrell, RPh, MBA, Associate Dean and Chair of the Pharmaceutical Business and Administrative Sciences Department at MCPHS University, delivered closing remarks for the evening and emphasized the importance that pharmacists have in this unique, up and coming field.
Many thanks to the MCPHS-Boston IPhO Student Chapter, including student leaders Vannary Chhay, Christine Marotta, Amy Trottier, Divyani Patel, Sarah Caisse, Judi Abboud, and James Geiser.
Authored by Adam Quicquaro, 2018 PharmD Candidate, 2016-17 MCPHS-Boston IPhO Chapter President